Abstract
Cost-effectiveness analyses are integrated in evidence-based recommendations for market access and reimbursement of new products, provided by health technology assessment (HTA) bodies, in several countries. The objective was to compare economic protocols submitted for a same product to three HTA bodies, assessing if the same cost-effectiveness analysis and methodology was implemented and if the results provided consistent ICERs.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
